A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
about
A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
description
im Oktober 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 24 October 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2018
@uk
name
A study of the circulating fib ...... direct-acting antiviral agents
@en
A study of the circulating fib ...... direct-acting antiviral agents
@nl
type
label
A study of the circulating fib ...... direct-acting antiviral agents
@en
A study of the circulating fib ...... direct-acting antiviral agents
@nl
prefLabel
A study of the circulating fib ...... direct-acting antiviral agents
@en
A study of the circulating fib ...... direct-acting antiviral agents
@nl
P2093
P2860
P356
P1476
A study of the circulating fib ...... direct-acting antiviral agents
@en
P2093
Aliaa S Abd-ElFattah
Asmaa K Ahmad
Ghada M El Sagheer
Lamia Hamdi
Zienab M Saad
P2860
P304
P356
10.2147/CEG.S173484
P407
P577
2018-10-24T00:00:00Z